Miami Breast Cancer Conference (MBCC) | Conference

Combination of Variables May Inform Oncologists on Residual Risk After Adjuvant Therapy for Breast Cancer
March 11, 2021

Independent variables, such as the burden of disease prior to treatment, molecular prognosis, sensitivity to chemotherapy, sensitivity to endocrine therapy, and sensitivity to other treatments could be effective in predicting risk of recurrence in patients with breast cancer.

Promising Antibody-Drug Conjugates Have the Potential to Change Treatment Landscape for HER2-Negative Breast Cancer
March 10, 2021

Kevin Kalinsky, MD, MS, discussed a number of antibody-drug conjugates, detailing the prevailing data and potential trials that may change the treatment paradigm for patients with breast cancer.

Preventing and Treating Cardiotoxicity in Patients With Breast Cancer Involves Aggressive Monitoring, Management Strategies
March 09, 2021

Mandar Aras, MD, PhD, discussed the management and prevention of cardiotoxicity in patients receiving systemic therapy for breast cancer at the 38th Annual Miami Breast Cancer Conference, hosted by Physicians’ Education Resource®, LLC.

Amended Protocols Allow for Reduced GI Toxicities With Oral Paclitaxel Combo in Metastatic Breast Cancer
March 06, 2021

Allowing for the use of antiemetic prophylaxis and anti-diarrheal medication in the phase 3 KX-ORAX-001 study reduced study drug-related gastrointestinal adverse events.

Adaptive Therapy Approach in HER2+ Early Breast Cancer May Improve Outcomes, Expert Says
March 05, 2021

At the Miami Breast Cancer Conference, Debu Tripathy, MD, reviewed adaptive therapy for the adjuvant treatment of patients with HER2-positive, early-stage breast cancer.

General Surgeons in Rural Areas Need Broad Skill Set for Delivery of Surgical Services
March 05, 2021

Data focusing on patients seeking breast surgical procedures determined that broad skill sets are valuable for general surgeons practicing in rural areas, as breast surgeries only represented a small proportion of total surgical procedures conducted.

Neratinib Combo Improves Outcomes in Patients With HER2+ Metastatic Breast Cancer With CNS Disease
March 05, 2021

The addition of neratinib to capecitabine improved progression-free survival and central nervous system outcomes in patients with HER2-positive metastatic breast cancer with central nervous system disease.

Adjuvant Therapy Selection by Recurrence Score After IORT May Lower Recurrence Rates for ER+ Early Breast Cancer
March 05, 2021

More patients with early-stage estrogen receptor–positive breast cancer with high recurrence scores received chemotherapy following radiation in a single-institution study, and this resulted in a low recurrence rate across all patients examined.

Tumor Cell Expression of PD-L1 is Key in Predicting Efficacy of Pembrolizumab for Patients With mTNBC
March 05, 2021

The analysis of the KEYNOTE-119 study presented at the Miami Breast Cancer Conference, hosted by Physicians’ Education Resource®, LLC®, found trends estimating a significant role for tumor cell expression in PD-L1 as a predictive biomarker for pembrolizumab efficacy.

Patricia Jakel, RN, MN, AOCN, On Treating Patients with CDK 4/6 Inhibitors
March 15, 2020

The clinical nurse specialist was also diagnosed with stage III invasive lobular breast cancer and was treated with CDK 4/6 inhibitors, giving her the unique opportunity to speak to both the patient and clinical perspective.